Sign in
CompletedPhase 2

Intravesical Lactobacillus to Reduce Urinary Symptoms After Spinal Cord Injury

Key facts

Who runs it
Medstar Health Research Institute
Where
Washington D.C., United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
182 people enrolled
Started
1 Jun 2020
Ended
14 Feb 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Culturelle 10 Billion CFU Capsule (2 doses)
  • Culturelle 10 Billion CFU Capsule (4 doses)
Record updated
3 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • SCI at least 1-year duration
  • Neurogenic bladder
  • Utilizing intermittent catheterization for bladder management
  • Women must be premenopausal and not currently menstruating
  • Community dwelling

Who cannot take part

  • Sexual activity within the previous 72 hours
  • Psychologic or psychiatric conditions influencing the ability to follow instructions
  • Use of prophylactic antibiotics
  • Instillation of intravesical antimicrobials to prevent UTI
  • Use of oral or IV antibiotics within the past 2 weeks
  • Participation in another study with which results could be confounded

Where in United States

  • MedStar National Rehabilitation HospitalWashington D.C., United States

About the trial

What the trial wants to find out

The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.

The 2 groups in the trial

  • Low Dosage GroupTreatment being tested

    For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 2 LGG capsules and will repeat this process the following day ("Low" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion.

    Treatment: Culturelle 10 Billion CFU Capsule (2 doses)

  • High Dosage GroupTreatment being tested

    For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses ("High" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion.

    Treatment: Culturelle 10 Billion CFU Capsule (4 doses)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
3 November 2026